SGRY Form 144: Insider Plans Sale of 100,000 Common Shares

Rhea-AI Filing Summary

Surgery Partners (SGRY) filed a Form 144 reporting a proposed sale of 100,000 common shares through UBS Financial Services on the NASDAQ approximately on 08/21/2025. The shares were acquired on 08/20/2025 via equity compensation from Surgery Partners, Inc., with an indicated aggregate market value of $2,299,020.90 based on 128,209,410 shares outstanding. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information. The notice also references compliance considerations for trading plans and Rule 10b5-1.

Positive

• Transparent disclosure of a proposed insider sale meeting Rule 144 notification requirements
• No sales in prior three months, indicating this is not part of a pattern of frequent insider disposals

Negative

• Insider liquidity event of 100,000 shares valued at approximately $2.30 million, which could modestly increase supply
• Rapid sale timing—shares were acquired 08/20/2025 with an approximate sale date of 08/21/2025

Insights

Securities Analyst

TL;DR: Routine insider sale notice for 100,000 shares acquired via equity compensation; limited immediate market impact.

This Form 144 documents a proposed sale of 100,000 common shares by a person who received the shares as equity compensation the day before the intended sale. The transaction is being routed through UBS on NASDAQ with an aggregate market value stated at $2.299 million. There are no reported sales in the prior three months. From a securities perspective, this filing appears procedural: it notifies the market of an intended resale under Rule 144 and includes the standard attestation about non-public material information.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; the filing signals standard insider liquidity rather than governance concerns.

The filer discloses acquisition via equity compensation and a near-term planned sale, and provides the customary representation regarding material nonpublic information and trading-plan considerations. The absence of prior sales in the three-month window is noted. This submission fulfills disclosure obligations and does not on its face indicate governance issues, but it does document insider monetization that stakeholders can observe.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	100000	2299020.9	128209410	08/21/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/20/2025	Equity Compensation	Surgery Partners, Inc.			100000	08/20/2025	Equity Option Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by Surgery Partners (SGRY) report?

The Form 144 reports a proposed sale of 100,000 common shares through UBS on NASDAQ, with an approximate sale date of 08/21/2025.

How were the 100,000 SGRY shares acquired?

The shares were acquired on 08/20/2025 as equity compensation from Surgery Partners, Inc., with payment described as an equity option exercise.

What is the aggregate market value reported for the proposed sale?

The aggregate market value is reported as $2,299,020.90 for the 100,000 shares.

Were any SGRY shares sold by the filer in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

Does the filing state the filer knows of any undisclosed material information?

The filer represents by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed.